Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0614)
Drug Name
Erythromycin stearate
Synonyms
Eratrex; Erypar; Erythrocin stearate; Erythromycin octadecanoate (salt); Erythromycin stearate (salt); Erythromycin stearate [BAN:JAN]; Erythromycin steraric acid salt; Erythromycin, stearate (salt); Ethril; Ethril 250; Gallimycin; HSDB 4178; LXW024X05M; Meberyt; NCI-C55674; OE 7; Octadecanoic acid, compd. with erythromycin (1:1); Pfizer-E; Qidmycin; Stearic acid, compd. with erythromycin (1:1); UNII-LXW024X05M; Wyamycin S; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erygel; Erymax; Erythra-Derm; Erythro-Statin; Erythrocin; Erythromycin; Erythrogran; Erythroguent; Erythromid; Erythromycin A; Erythromycin base; Erythromycine; Erythromycinum; Ilocaps; Ilotycin; Mephamycin; Pantomicina; Propiocine; R-P Mycin; Robimycin; Sansac; Stiemycin; Torlamicina; Wemid; Erythro; (-)-ERYTHROMYCIN; 114-07-8; Abboticin; Abomacetin; Akne-Mycin; Benzamycin; Dotycin; Dumotrycin; E-Base; E-Glades; E-Mycin; E-Solve 2; Emgel; Eritrocina; Eritromicina; Ery-Tab; Eryacne; Eryc 125; Eryc Sprinkles; 643-22-1; Abboticine; Bristamycin; CCRIS 1504; Dowmycin E; EINECS 211-396-1; ERYTHROMYCIN STEARATE; ETHRIL 500
Indication Acute upper respiratory infection [ICD11: CA07] Approved [1]
Structure
3D MOL is unavailable 2D MOL
Pharmaceutical Properties Molecular Weight 1018.4 Topological Polar Surface Area 231
Heavy Atom Count 71 Rotatable Bond Count 23
Hydrogen Bond Donor Count 6 Hydrogen Bond Acceptor Count 16
Cross-matching ID
PubChem CID
12559
ChEBI ID
CHEBI:34742
CAS Number
643-22-1
TTD Drug ID
D02YIZ
Formula
C55H103NO15
Canonical SMILES
CCCCCCCCCCCCCCCCCC(=O)O.CCC1C(C(C(C(=O)C(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)O)(C)O
InChI
1S/C37H67NO13.C18H36O2/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3;2-17H2,1H3,(H,19,20)/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-;/m1./s1
InChIKey
YAVZHCFFUATPRK-YZPBMOCRSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Erythromycin DM002007
12560
Hydrolysis - Hydrolysis 1 [10]
N-Desmethylerythromycin DM002008
10010092
Oxidation - Demethylation 2 [11] , [12] , [9]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR000940 Erythromycin stearate Erythromycin Hydrolysis - Hydrolysis Unclear [10]
MR000939 Erythromycin N-Desmethylerythromycin Oxidation - Demethylation CYP4F11 ... [11], [12], [9]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Beta-glucuronidase (uidA) DME1042 Lactobacillus sakei
A0A2A5L2J1_LACRH
3.2.1.31
[2] , [3]
Cytochrome P450 1A1 (CYP1A1) DME0006 Homo sapiens
CP1A1_HUMAN
1.14.14.1
[4]
Cytochrome P450 1A2 (CYP1A2) DME0003 Homo sapiens
CP1A2_HUMAN
1.14.14.1
[5]
Cytochrome P450 1B1 (CYP1B1) DME0023 Homo sapiens
CP1B1_HUMAN
1.14.14.1
[4]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[6]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[7]
Cytochrome P450 3A7 (CYP3A7) DME0015 Homo sapiens
CP3A7_HUMAN
1.14.14.1
[8]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DME0616 Homo sapiens
CP4FB_HUMAN
1.14.14.1
[9]
⏷ Show the Full List of 8  DME(s)
References
1 Erythromycin Stearate was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
3 Degradation of various insecticides in cooked eggs during in vitro human digestion. Environ Pollut. 2018 Dec;243(Pt A):437-443.
4 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
5 Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
6 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
7 Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
8 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
9 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
10 Hazardous Substances Data Bank:ERYTHROMYCIN STEARATE
11 PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics Pharmacogenet Genomics. 2017 Apr;27(4):164-167. doi: 10.1097/FPC.0000000000000270.
12 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism Clin Pharmacol Ther. 2011 May;89(5):693-701. doi: 10.1038/clpt.2011.25.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.